Article info

Download PDFPDF
Systematic review
Combination therapy with long-acting β-agonists plus inhaled corticosteroids is no more effective than LABA monotherapy for mortality outcomes and severe exacerbations in moderate to very severe COPD and is associated with serious adverse effects

Authors

  1. Correspondence to Peter Anthony Frith
    Professor in Respiratory Medicine, Flinders University of South Australia, Bedford Park 5042, Respiratory Allergy and Sleep Services, Repatriation General Hospital, Daw Park 5041, Australia; peter.frith{at}health.sa.gov.au
View Full Text

Citation

Frith PA
Combination therapy with long-acting β-agonists plus inhaled corticosteroids is no more effective than LABA monotherapy for mortality outcomes and severe exacerbations in moderate to very severe COPD and is associated with serious adverse effects

Publication history

  • First published June 3, 2010.
Online issue publication 
October 25, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.